Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test. The results of the analysis show that the test should retain full reactivity against mpox strains circulating over the last year, including clade 1b.
On August 13, 2024, the Africa Centres for Disease Control and Prevention (Africa CDC) declared mpox (formerly monkeypox) a Public Health Emergency of Continental Security (PHECS), which was followed the next day by the World Health Organization Director-General declaring the illness a public health emergency of international concern (PHEIC). On August 27, 2024, the Africa CDC reported that mpox infections in Africa had reached more than 22,800 cases, resulting in 622 deaths. Clade Ib mpox appears to be more transmissible between humans and more severe than clade Ia or clade II, the version responsible for the 2022 mpox outbreak.
In response to the outbreak in 2022, Co-Dx designed and verified two Research Use Only (RUO) tests for mpox* virus on the Company's patented Co-Primers® platform. The version of the test evaluated in the recent in silico analysis (a type of experiment performed by computer to compare the test's primer sequences against known strains of mpox) was the 2-gene version of the Company's mpox test. This test was also included in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December, 2023, which showed that the Co-Dx test performed better at detection of mpox from saliva samples than the other assays surveyed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.